<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515723</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH063985-04</org_study_id>
    <secondary_id>R01MH063985-04</secondary_id>
    <nct_id>NCT00515723</nct_id>
  </id_info>
  <brief_title>Glucose and Lipid Metabolism on Antipsychotic Medication</brief_title>
  <acronym>Glulipid</acronym>
  <official_title>Glucose and Lipid Metabolism on Antipsychotic Medication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to a) evaluate the effects of selected antipsychotic medications on insulin
      action in skeletal muscle (glucose disposal), liver (glucose production) and adipose tissue
      (whole-body lipolysis), b) evaluate the effects of selected antipsychotic medications on
      abdominal adipose tissue mass, total body fat and total fat-free mass, and c) explore the
      longitudinal effects of treatment with selected antipsychotics on glucose tolerance, lipid
      profiles, abdominal adipose tissue mass, total body fat and total fat-free mass. These
      hypotheses will be evaluated by measuring 1) whole-body glucose and lipid kinetics with the
      use of &quot;gold-standard&quot; stable isotope tracer methodology, 2) body composition using dual
      energy x-ray absorptiometry and magnetic resonance imaging, and 3) longitudinal changes in
      glucose tolerance and lipid profiles. The aims will be addressed in non-diabetic
      schizophrenia patients chronically treated with risperidone, olanzapine, clozapine,
      quetiapine, ziprasidone, or haloperidol, and untreated healthy controls. Re-evaluations will
      also be performed in patients who are randomized to switch from their current antipsychotic
      (from the above groups) to risperidone, olanzapine, quetiapine, or ziprasidone for 6 months.
      Relevant data is critically needed to target basic research, identify long-term
      cardiovascular consequences, and plan therapeutic interventions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the
      general population. Type 2 diabetes mellitus is characterized by disturbances in insulin
      action on skeletal muscle, liver and adipose tissue. Diabetes causes increased morbidity and
      mortality due to acute (e.g., diabetic ketoacidosis) and long-term (e.g., cardiovascular
      disease) complications. The combination of hyperglycemia, dyslipidemia and abdominal
      adiposity is even more strongly associated with increased cardiovascular morbidity and
      mortality. The association of type 2 diabetes and hyperglycemia with schizophrenia was first
      noted prior to the introduction of antipsychotic medications, suggesting that these patients
      may be at increased risk. Since then, however, additional glucoregulatory abnormalities
      (e.g., new onset diabetes), dyslipidemia, and increased weight and adiposity have all been
      associated with antipsychotic medications. Concern about antipsychotic effects on glucose,
      lipids and adiposity has increased recently, focusing on the widely-used newer medications,
      clozapine and olanzapine. Increased abdominal adiposity can secondarily decrease insulin
      sensitivity and antipsychotics can increase adiposity. However, medication effects on glucose
      control and insulin action may also occur independent of differences in adiposity. This
      project aims to a) evaluate the effects of selected antipsychotic medications on insulin
      action in skeletal muscle (glucose disposal), liver (glucose production) and adipose tissue
      (whole-body lipolysis), b) evaluate the effects of selected antipsychotic medications on
      abdominal adipose tissue mass, total body fat and total fat-free mass, and c) explore the
      longitudinal effects of treatment with selected antipsychotics on glucose tolerance, lipid
      profiles, abdominal adipose tissue mass, total body fat and total fat-free mass. These
      hypotheses will be evaluated by measuring 1) whole-body glucose and lipid kinetics with the
      use of &quot;gold-standard&quot; stable isotope tracer methodology, 2) body composition using dual
      energy x-ray absorptiometry and magnetic resonance imaging, and 3) longitudinal changes in
      glucose tolerance and lipid profiles. The aims will be addressed in non-diabetic
      schizophrenia patients chronically treated with risperidone, olanzapine, clozapine,
      quetiapine, ziprasidone, or haloperidol, and untreated healthy controls. Re-evaluations will
      also be performed in patients who are randomized to switch from their current antipsychotic
      (from the above groups) to risperidone, olanzapine, quetiapine, or ziprasidone for 6 months.
      Relevant data is critically needed to target basic research, identify long-term
      cardiovascular consequences, and plan therapeutic interventions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DEXA Total Fat</measure>
    <time_frame>The relevant time points include baseline, week 6 and week 12.</time_frame>
    <description>This study hypothesized that antipsychotic treatment would increase total body fat, as measured by whole body dual energy x-ray absorptiometry (DEXA), with larger adverse effects for olanzapine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clamp Derived Insulin Sensitivity (mg/kg/Min)</measure>
    <time_frame>The relevant time points include baseline and week 12.</time_frame>
    <description>This study hypothesized that antipsychotic treatment would decrease insulin sensitivity, with larger adverse effects for olanzapine. Insulin sensitivity describes how sensitive the body is to the effects of insulin.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group were randomized to flexibly-dosed treatment with olanzapine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group were randomized to flexibly-dosed treatment with risperidone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group were randomized to flexibly-dosed treatment with quetiapine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ziprasidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group were randomized to flexibly-dosed treatment with ziprasidone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <description>randomized to 12 week trial of risperidone.</description>
    <arm_group_label>Risperidone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>randomized to 12 week trial of olanzapine.</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine</intervention_name>
    <description>randomized to 12 week trial of quetiapine.</description>
    <arm_group_label>Quetiapine</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziprasidone</intervention_name>
    <description>randomized to 12 week trial of ziprasidone.</description>
    <arm_group_label>Ziprasidone</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-60 years

          -  Patients: otherwise healthy and meets DSM-IV criteria for schizophrenia or
             schizoaffective disorder, any type, treated with haloperidol, olanzapine, clozapine,
             quetiapine, ziprasidone, aripiprazole, or risperidone for at least 3 months

          -  Controls: healthy

          -  Able to give informed consent

          -  No antipsychotic medication changes for 3 months, and no other medication changes for
             2 weeks prior to Baseline Evaluations.

        Exclusion Criteria:

          -  Axis I psychiatric disorder criteria met in self except for substance use disorders as
             below

          -  Patients and controls: meets DSM-IV criteria for the diagnoses of substance abuse
             within the past 3 months

          -  Involuntary legal status (as per Missouri law)

          -  The presence of any serious medical disorder that may confound the assessment of
             relevant biologic measures or diagnosis, including: significant organ system
             dysfunction, metabolic diseases, type 1 diabetes mellitus, symptomatic type 2 diabetes
             mellitus (see below), pregnancy, endocrine disease, coagulopathy, clinically
             significant anemia, that would preclude blood sampling (as determined by the PI) or
             acute infection;

          -  Patients taking more than one atypical antipsychotic medication;

          -  Subjects taking certain prescription medications (as determined by PI on a case by
             case basis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Newcomer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Univerisity School of Medicine and Florida Atlantic University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Univeristy School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Psychiatry Dept.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 13, 2007</study_first_submitted>
  <study_first_submitted_qc>August 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2007</study_first_posted>
  <results_first_submitted>July 20, 2018</results_first_submitted>
  <results_first_submitted_qc>October 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2019</results_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>control</keyword>
  <keyword>risperidone</keyword>
  <keyword>olanzapine</keyword>
  <keyword>quetiapine</keyword>
  <keyword>ziprasidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from wide range of sites in the St. Louis community. Some advertising with flyers was used however the majority of the recruitment was done using community outreach,doctor-to-doctor or self-referrals, and referrals from board and care and community support programs. All recruitment materials were approved by the IRB.</recruitment_details>
      <pre_assignment_details>Participants were enrolled in the study once they signed consent. After enrollment, participants were brought in for a screening visit consisting of a diagnostic interview, screening labs, a review of records and a discussion with their primary psychiatrist. If the patient met all inclusion criteria after screening, study visits were scheduled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olanzapine</title>
          <description>Participants in this group were randomized to flexibly-dosed treatment with olanzapine.</description>
        </group>
        <group group_id="P2">
          <title>Risperidone</title>
          <description>Participants in this group were randomized to flexibly-dosed treatment with risperidone.</description>
        </group>
        <group group_id="P3">
          <title>Quetiapine</title>
          <description>Participants in this group were randomized to flexibly-dosed treatment with quetiapine.</description>
        </group>
        <group group_id="P4">
          <title>Ziprasidone</title>
          <description>Participants in this group were randomized to flexibly-dosed treatment with ziprasidone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olanzapine</title>
          <description>Participants with schizophrenia were randomized to olanzapine.</description>
        </group>
        <group group_id="B2">
          <title>Risperidone</title>
          <description>Patients with schizophrenia were randomized to risperidone.</description>
        </group>
        <group group_id="B3">
          <title>Quetiapine</title>
          <description>Participants with schizophrenia were randomized to quetiapine.</description>
        </group>
        <group group_id="B4">
          <title>Ziprasidone</title>
          <description>Participants with schizophrenia were randomized to ziprasidone.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.5" spread="11.2"/>
                    <measurement group_id="B2" value="39.2" spread="11.1"/>
                    <measurement group_id="B3" value="36.4" spread="8.6"/>
                    <measurement group_id="B4" value="38.3" spread="10.2"/>
                    <measurement group_id="B5" value="37.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.75" spread="21.04"/>
                    <measurement group_id="B2" value="93.88" spread="19.19"/>
                    <measurement group_id="B3" value="92.95" spread="18.67"/>
                    <measurement group_id="B4" value="94.68" spread="15.90"/>
                    <measurement group_id="B5" value="95.16" spread="18.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilograms per squared meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.27" spread="7.38"/>
                    <measurement group_id="B2" value="31.04" spread="6.50"/>
                    <measurement group_id="B3" value="31.76" spread="6.63"/>
                    <measurement group_id="B4" value="32.27" spread="5.56"/>
                    <measurement group_id="B5" value="31.87" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.44" spread="16.74"/>
                    <measurement group_id="B2" value="102.87" spread="16.66"/>
                    <measurement group_id="B3" value="104.10" spread="15.45"/>
                    <measurement group_id="B4" value="108.50" spread="15.18"/>
                    <measurement group_id="B5" value="106.19" spread="15.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DEXA Total Fat</title>
          <population>3 participants were missing a baseline DEXA scan.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.24" spread="13.49"/>
                    <measurement group_id="B2" value="24.95" spread="10.07"/>
                    <measurement group_id="B3" value="28.69" spread="11.63"/>
                    <measurement group_id="B4" value="31.60" spread="11.22"/>
                    <measurement group_id="B5" value="29.68" spread="11.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Whole Body Sensitivity</title>
          <population>Two participants were missing data due to bad veins.</population>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.39" spread="2.16"/>
                    <measurement group_id="B2" value="5.53" spread="3.32"/>
                    <measurement group_id="B3" value="5.10" spread="2.93"/>
                    <measurement group_id="B4" value="4.33" spread="2.01"/>
                    <measurement group_id="B5" value="4.79" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>DEXA Total Fat</title>
        <description>This study hypothesized that antipsychotic treatment would increase total body fat, as measured by whole body dual energy x-ray absorptiometry (DEXA), with larger adverse effects for olanzapine.</description>
        <time_frame>The relevant time points include baseline, week 6 and week 12.</time_frame>
        <population>Modified Intent to Treat (ITT) sample with week 0, week 6 and week 12 data. Two Quetiapine participants were excluded from analyses due to failure to adhere to the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Participants in this group were randomized to flexibly-dosed treatment with olanzapine.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Participants in this group were randomized to flexibly-dosed treatment with risperidone.</description>
          </group>
          <group group_id="O3">
            <title>Quetiapine</title>
            <description>Participants in this group were randomized to flexibly-dosed treatment with quetiapine.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone</title>
            <description>Participants in this group were randomized to flexibly-dosed treatment with ziprasidone.</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>This arm consists of all treatments pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>DEXA Total Fat</title>
          <description>This study hypothesized that antipsychotic treatment would increase total body fat, as measured by whole body dual energy x-ray absorptiometry (DEXA), with larger adverse effects for olanzapine.</description>
          <population>Modified Intent to Treat (ITT) sample with week 0, week 6 and week 12 data. Two Quetiapine participants were excluded from analyses due to failure to adhere to the protocol.</population>
          <units>kilograms of body fat</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.24" spread="2.48"/>
                    <measurement group_id="O2" value="27.66" spread="2.64"/>
                    <measurement group_id="O3" value="28.83" spread="2.77"/>
                    <measurement group_id="O4" value="31.60" spread="2.38"/>
                    <measurement group_id="O5" value="30.25" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.38" spread="2.48"/>
                    <measurement group_id="O2" value="28.29" spread="2.64"/>
                    <measurement group_id="O3" value="29.60" spread="2.77"/>
                    <measurement group_id="O4" value="31.18" spread="2.39"/>
                    <measurement group_id="O5" value="31.05" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.45" spread="2.49"/>
                    <measurement group_id="O2" value="29.23" spread="2.64"/>
                    <measurement group_id="O3" value="30.10" spread="2.77"/>
                    <measurement group_id="O4" value="30.66" spread="2.40"/>
                    <measurement group_id="O5" value="31.52" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Primary analysis for change in DEXA total fat used a likelihood-based mixed-effects model using time (0, 6, and 12 weeks) as the independent variable, with Toeplitz covariance structure specified, based on Akaike Information Criterion-Corrected (AIC-C). The null hypothesis was that there was no difference in the outcome over time (main effect of time).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>The a priori threshold for statistical significance in this planned primary test was p&lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Primary analysis for change in DEXA total fat used a likelihood-based mixed-effects model using time (0, 6, and 12 weeks) and treatment group as independent variables, with Toeplitz covariance structure specified, based on Akaike Information Criterion-Corrected (AIC-C). The null hypothesis was that there were no differences between groups in the change over time (time by treatment condition).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>The a priori threshold for statistical significance in this planned primary test was p&lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clamp Derived Insulin Sensitivity (mg/kg/Min)</title>
        <description>This study hypothesized that antipsychotic treatment would decrease insulin sensitivity, with larger adverse effects for olanzapine. Insulin sensitivity describes how sensitive the body is to the effects of insulin.</description>
        <time_frame>The relevant time points include baseline and week 12.</time_frame>
        <population>Modified Intent to Treat (ITT) sample with Week 0 and Week 12 data. Two Quetiapine participants were excluded from analyses due to failure to adhere to the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Participants in this group were randomized to flexibly-dosed treatment with olanzapine.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Participants in this group were randomized to flexibly-dosed treatment with risperidone.</description>
          </group>
          <group group_id="O3">
            <title>Quetiapine</title>
            <description>Participants in this group were randomized to flexibly-dosed treatment with quetiapine.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone</title>
            <description>Participants in this group were randomized to flexibly-dosed treatment with ziprasidone.</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>This arm consists of all treatments pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Clamp Derived Insulin Sensitivity (mg/kg/Min)</title>
          <description>This study hypothesized that antipsychotic treatment would decrease insulin sensitivity, with larger adverse effects for olanzapine. Insulin sensitivity describes how sensitive the body is to the effects of insulin.</description>
          <population>Modified Intent to Treat (ITT) sample with Week 0 and Week 12 data. Two Quetiapine participants were excluded from analyses due to failure to adhere to the protocol.</population>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="0.53"/>
                    <measurement group_id="O2" value="5.53" spread="0.57"/>
                    <measurement group_id="O3" value="5.28" spread="0.58"/>
                    <measurement group_id="O4" value="4.33" spread="0.50"/>
                    <measurement group_id="O5" value="4.82" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.62" spread="0.49"/>
                    <measurement group_id="O2" value="5.01" spread="0.51"/>
                    <measurement group_id="O3" value="5.08" spread="0.53"/>
                    <measurement group_id="O4" value="4.45" spread="0.47"/>
                    <measurement group_id="O5" value="4.50" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Primary analysis for change in insulin sensitivity used a likelihood-based mixed-effects model using time (0 and 12 weeks) as the independent variable, with an unstructured covariance structure specified, based on the Akaike Information Criterion-Corrected (AIC-C). The null hypothesis was that there was no difference in the outcome over time (main effect of time).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>The a priori threshold for statistical significance in this planned primary test was p&lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Primary analysis for change in insulin sensitivity used a likelihood-based mixed-effects model using time (0 and 12 weeks) and treatment group as the independent variables, with an unstructured covariance structure specified, based on the Akaike Information Criterion-Corrected (AIC-C). The null hypothesis was that there were no differences between groups in the change over time (time by treatment condition).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.22</p_value>
            <p_value_desc>The a priori threshold for statistical significance in this planned primary test was p&lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the study's primary time points, baseline and week 12. However, only adverse events at week 12 are provided as these are potentially related to the treatments. As a result, the sample sizes differ from the sample sizes found in the Participant Flow section as not everyone made it to week 12.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Olanzapine</title>
          <description>Participants with schizophrenia were randomized to olanzapine.</description>
        </group>
        <group group_id="E2">
          <title>Risperidone</title>
          <description>Patients with schizophrenia were randomized to risperidone.</description>
        </group>
        <group group_id="E3">
          <title>Quetiapine</title>
          <description>Participants with schizophrenia were randomized to quetiapine.</description>
        </group>
        <group group_id="E4">
          <title>Ziprasidone</title>
          <description>Participants with schizophrenia were randomized to ziprasidone.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness/Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tiredness/Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Difficulty Concentrating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Newcomer, M.D.</name_or_title>
      <organization>Washington University School of Medicine and Florida Atlantic University</organization>
      <phone>561-297-0252</phone>
      <email>jnewcomer@fau.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

